Referências
Principais artigos
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: esophageal and esophagogastric junction cancers [internet publication].Texto completo
Obermannová R, Alsina M, Cervantes A, et al; ESMO Guidelines Committee. Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Oct;33(10):992-1004.Texto completo Resumo
van Hagen P, Hulshof MC, van Lanschot JJ, et al; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012 May 31;366(22):2074-84.Texto completo Resumo
Shapiro J, van Lanschot JJ, Hulshof MC, et al; CROSS study group. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015 Sep;16(9):1090-8. Resumo
Artigos de referência
1. Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020 Jan;76(2):182-8.Texto completo Resumo
2. Patel N, Benipal B. Incidence of esophageal cancer in the United States from 2001-2015: a United States Cancer Statistics analysis of 50 states. Cureus. 2018 Dec 10;10(12):e3709.Texto completo Resumo
3. Thrumurthy SG, Chaudry MA, Thrumurthy SSD, et al. Oesophageal cancer: risks, prevention, and diagnosis. BMJ. 2019 Jul 9;366:l4373. Resumo
4. Rüdiger Siewert J, Feith M, Werner M, et al. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg. 2000 Sep;232(3):353-61.Texto completo Resumo
5. Curtis NJ, Noble F, Bailey IS, et al. The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction. J Surg Oncol. 2014 Mar;109(3):202-7.Texto completo Resumo
6. Uhlenhopp DJ, Then EO, Sunkara T, et al. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol. 2020 Dec;13(6):1010-21. Resumo
7. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209-49.Texto completo Resumo
8. National Cancer Institute: Surveillance, Epidemiology, and End Results Program (SEER). Cancer stat facts: esophageal cancer. 2023 [internet publication].Texto completo
9. American Cancer Society. Cancer facts & figures 2024. 2024 [internet publication].Texto completo
10. Corley DA, Buffler PA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol. 2001 Dec;30(6):1415-25.Texto completo Resumo
11. Huang J, Koulaouzidis A, Marlicz W, et al. Global burden, risk factors, and trends of esophageal cancer: an analysis of cancer registries from 48 countries. Cancers (Basel). 2021 Jan 5;13(1):141.Texto completo Resumo
12. Demeester SR. Epidemiology and biology of esophageal cancer. Gastrointest Cancer Res. 2009;3(2 suppl 1):S2-5.Texto completo Resumo
13. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008 Aug 20;100(16):1184-7.Texto completo Resumo
14. Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends - an update. Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27.Texto completo Resumo
15. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: esophageal and esophagogastric junction cancers [internet publication].Texto completo
16. Cummings LC, Cooper GS. Descriptive epidemiology of esophageal carcinoma in the Ohio Cancer Registry. Cancer Detect Prev. 2008;32(1):87-92. Resumo
17. Chen S, Zhou K, Yang L, et al. Racial differences in esophageal squamous cell carcinoma: incidence and molecular features. Biomed Res Int. 2017;2017:1204082.Texto completo Resumo
18. Baquet CR, Commiskey P, Mack K, et al. Esophageal cancer epidemiology in blacks and whites: racial and gender disparities in incidence, mortality, survival rates and histology. J Natl Med Assoc. 2005 Nov;97(11):1471-8.Texto completo Resumo
19. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Esophagus: SEER incidence rates by age at diagnosis, 2015-2019. 2023 [internet publication].Texto completo
20. Xie SH, Lagergren J. The male predominance in esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2016 Mar;14(3):338-47.Texto completo Resumo
21. He H, Chen N, Hou Y, et al. Trends in the incidence and survival of patients with esophageal cancer: a SEER database analysis. Thorac Cancer. 2020 May;11(5):1121-8.Texto completo Resumo
22. Lagergren J. Etiology and risk factors for oesophageal adenocarcinoma: possibilities for chemoprophylaxis? Best Pract Res Clin Gastroenterol. 2006;20(5):803-12. Resumo
23. Tustumi F, Bernardo WM, da Rocha JRM, et al. Esophageal achalasia: a risk factor for carcinoma. A systematic review and meta-analysis. Dis Esophagus. 2017 Oct 1;30(10):1-8.Texto completo Resumo
24. Nesteruk K, Spaander MCW, Leeuwenburgh I, et al. Achalasia and associated esophageal cancer risk: what lessons can we learn from the molecular analysis of Barrett's-associated adenocarcinoma? Biochim Biophys Acta Rev Cancer. 2019 Dec;1872(2):188291.Texto completo Resumo
25. Kamangar F, Chow WH, Abnet CC, et al. Environmental causes of esophageal cancer. Gastroenterol Clin North Am. 2009 Mar;38(1):27-57, vii. Resumo
26. Freedman ND, Abnet CC, Leitzmann MF, et al. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol. 2007 Jun 15;165(12):1424-33.Texto completo Resumo
27. Cook MB, Kamangar F, Whiteman DC, et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst. 2010 Sep 8;102(17):1344-53.Texto completo Resumo
28. Gregson EM, Bornschein J, Fitzgerald RC. Genetic progression of Barrett's oesophagus to oesophageal adenocarcinoma. Br J Cancer. 2016 Aug 9;115(4):403-10.Texto completo Resumo
29. Cossentino MJ, Wong RK. Barrett's esophagus and risk of esophageal adenocarcinoma. Semin Gastrointest Dis. 2003 Jul;14(3):128-35. Resumo
30. Kastelein F, van Olphen S, Steyerberg EW, et al. Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis. Gut. 2015 Jun;64(6):864-71. Resumo
31. Verbeek RE, Spittuler LF, Peute A, et al. Familial clustering of Barrett's esophagus and esophageal adenocarcinoma in a European cohort. Clin Gastroenterol Hepatol. 2014 Oct;12(10):1656-63.e1.Texto completo Resumo
32. Lagergren J, Bergström R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999 Mar 18;340(11):825-31.Texto completo Resumo
33. Alexandre L, Broughton T, Loke Y, et al. Meta-analysis: risk of esophageal adenocarcinoma with medications which relax the lower esophageal sphincter. Dis Esophagus. 2012 Aug;25(6):535-44.Texto completo Resumo
34. Fang X, Wei J, He X, et al. Quantitative association between body mass index and the risk of cancer: a global meta-analysis of prospective cohort studies. Int J Cancer. 2018 Oct 1;143(7):1595-603.Texto completo Resumo
35. Petrick JL, Jensen BW, Sørensen TIA, et al. Overweight patterns between childhood and early adulthood and esophageal and gastric cardia adenocarcinoma risk. Obesity (Silver Spring). 2019 Sep;27(9):1520-6.Texto completo Resumo
36. Samanic C, Chow WH, Gridley G, et al. Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control. 2006 Sep;17(7):901-9. Resumo
37. Chow WH, Blot WJ, Vaughan TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst. 1998 Jan 21;90(2):150-5.Texto completo Resumo
38. Lagergren J, Bergström R, Nyrén O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med. 1999 Jun 1;130(11):883-90. Resumo
39. Smith M, Zhou M, Whitlock G, et al. Esophageal cancer and body mass index: results from a prospective study of 220,000 men in China and a meta-analysis of published studies. Int J Cancer. 2008 Apr 1;122(7):1604-10.Texto completo Resumo
40. Tian J, Zuo C, Liu G, et al. Cumulative evidence for the relationship between body mass index and the risk of esophageal cancer: an updated meta-analysis with evidence from 25 observational studies. J Gastroenterol Hepatol. 2020 May;35(5):730-43. Resumo
41. Jin Y, Yang T, Li D, et al. Effect of dietary cholesterol intake on the risk of esophageal cancer: a meta-analysis. J Int Med Res. 2019 Sep;47(9):4059-68.Texto completo Resumo
42. O'Doherty MG, Cantwell MM, Murray LJ, et al. Dietary fat and meat intakes and risk of reflux esophagitis, Barrett's esophagus and esophageal adenocarcinoma. Int J Cancer. 2011 Sep 15;129(6):1493-502.Texto completo Resumo
43. Bagnardi V, Rota M, Botteri E, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer. 2015 Feb 3;112(3):580-93.Texto completo Resumo
44. Oze I, Charvat H, Matsuo K, et al. Revisit of an unanswered question by pooled analysis of eight cohort studies in Japan: does cigarette smoking and alcohol drinking have interaction for the risk of esophageal cancer? Cancer Med. 2019 Oct;8(14):6414-25.Texto completo Resumo
45. Salaspuro MP. Alcohol consumption and cancer of the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2003 Aug;17(4):679-94. Resumo
46. Wang J, Zhao L, Yan H, et al. A meta-analysis and systematic review on the association between human papillomavirus (types 16 and 18) infection and esophageal cancer worldwide. PLoS One. 2016 Jul 13;11(7):e0159140.Texto completo Resumo
47. Zhang SK, Guo LW, Chen Q, et al. The association between human papillomavirus 16 and esophageal cancer in Chinese population: a meta-analysis. BMC Cancer. 2015;15:1096.Texto completo Resumo
48. Guo LW, Zhang SK, Liu SZ, et al. Human papillomavirus type-18 prevalence in oesophageal cancer in the Chinese population: a meta-analysis. Epidemiol Infect. 2016 Feb;144(3):469-77.Texto completo Resumo
49. Liyanage SS, Rahman B, Ridda I, et al. The aetiological role of human papillomavirus in oesophageal squamous cell carcinoma: a meta-analysis. PLoS One. 2013 Jul 24;8(7):e69238.Texto completo Resumo
50. Koshiol J, Kreimer AR. Lessons from Australia: human papillomavirus is not a major risk factor for esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1889-92.Texto completo Resumo
51. Lagergren J, Wang Z, Bergström R, et al. Human papillomavirus infection and esophageal cancer: a nationwide seroepidemiologic case-control study in Sweden. J Natl Cancer Inst. 1999 Jan 20;91(2):156-62.Texto completo Resumo
52. Malekshah AF, Kimiagar M, Pourshams A, et al. Vitamin deficiency in Golestan Province, northern Iran: a high-risk area for esophageal cancer. Arch Iran Med. 2010 Sep;13(5):391-4. Resumo
53. Huang GL, Yang L, Su M, et al. Vitamin D3 and beta-carotene deficiency is associated with risk of esophageal squamous cell carcinoma - results of a case-control study in China. Asian Pac J Cancer Prev. 2014;15(2):819-23.Texto completo Resumo
54. Chen T, Cheng H, Chen X, et al. Family history of esophageal cancer increases the risk of esophageal squamous cell carcinoma. Sci Rep. 2015 Nov 3;5:16038.Texto completo Resumo
55. Gao Y, Hu N, Han X, et al. Family history of cancer and risk for esophageal and gastric cancer in Shanxi, China. BMC Cancer. 2009 Aug 5;9:269.Texto completo Resumo
56. Andrici J, Eslick GD. Maté consumption and the risk of esophageal squamous cell carcinoma: a meta-analysis. Dis Esophagus. 2013 Nov-Dec;26(8):807-16.Texto completo Resumo
57. Lubin JH, De Stefani E, Abnet CC, et al. Maté drinking and esophageal squamous cell carcinoma in South America: pooled results from two large multicenter case-control studies. Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):107-16.Texto completo Resumo
58. Islami F, Boffetta P, Ren JS, et al. High-temperature beverages and foods and esophageal cancer risk - a systematic review. Int J Cancer. 2009 Aug 1;125(3):491-524.Texto completo Resumo
59. Tai WP, Nie GJ, Chen MJ, et al. Hot food and beverage consumption and the risk of esophageal squamous cell carcinoma: a case-control study in a northwest area in China. Medicine (Baltimore). 2017 Dec;96(50):e9325.Texto completo Resumo
60. Chen Y, Tong Y, Yang C, et al. Consumption of hot beverages and foods and the risk of esophageal cancer: a meta-analysis of observational studies. BMC Cancer. 2015 Jun 2;15:449.Texto completo Resumo
61. Middleton DR, Menya D, Kigen N, et al. Hot beverages and oesophageal cancer risk in western Kenya: Findings from the ESCCAPE case-control study. Int J Cancer. 2019 Jun 1;144(11):2669-76.Texto completo Resumo
62. Abnet CC, Kamangar F, Islami F, et al. Tooth loss and lack of regular oral hygiene are associated with higher risk of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3062-8.Texto completo Resumo
63. Dar NA, Islami F, Bhat GA, et al. Poor oral hygiene and risk of esophageal squamous cell carcinoma in Kashmir. Br J Cancer. 2013 Sep 3;109(5):1367-72.Texto completo Resumo
64. Menya D, Maina SK, Kibosia C, et al. Dental fluorosis and oral health in the African Esophageal Cancer Corridor: findings from the Kenya ESCCAPE case-control study and a pan-African perspective. Int J Cancer. 2019 Jul 1;145(1):99-109.Texto completo Resumo
65. Arora H, Chacon AH, Choudhary S, et al. Bloom syndrome. Int J Dermatol. 2014 Jul;53(7):798-802. Resumo
66. Nalepa G, Clapp DW. Fanconi anaemia and cancer: an intricate relationship. Nat Rev Cancer. 2018 Mar;18(3):168-85. Resumo
67. Cameron AJ. Epidemiology of Barrett's esophagus and adenocarcinoma. Dis Esophagus. 2002;15(2):106-8.Texto completo Resumo
68. Lagergren J, Bergström R, Adami HO, et al. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med. 2000 Aug 1;133(3):165-75. Resumo
69. Freedman ND, Murray LJ, Kamangar F, et al. Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut. 2011 Aug;60(8):1029-37.Texto completo Resumo
70. Steevens J, Schouten LJ, Goldbohm RA, et al. Alcohol consumption, cigarette smoking and risk of subtypes of oesophageal and gastric cancer: a prospective cohort study. Gut. 2010 Jan;59(1):39-48. Resumo
71. Bracesco N, Sanchez AG, Contreras V, et al. Recent advances on Ilex paraguariensis research: minireview. J Ethnopharmacol. 2011 Jul 14;136(3):378-84. Resumo
72. Sewram V, De Stefani E, Brennan P, et al. Maté consumption and the risk of squamous cell esophageal cancer in uruguay. Cancer Epidemiol Biomarkers Prev. 2003 Jun;12(6):508-13. Resumo
73. Castellsagué X, Muñoz N, De Stefani E, et al. Influence of mate drinking, hot beverages and diet on esophageal cancer risk in South America. Int J Cancer. 2000 Nov 15;88(4):658-64.Texto completo Resumo
74. Vingeliene S, Chan DSM, Vieira AR, et al. An update of the WCRF/AICR systematic literature review and meta-analysis on dietary and anthropometric factors and esophageal cancer risk. Ann Oncol. 2017 Oct 1;28(10):2409-19.Texto completo Resumo
75. Liu J, Wang J, Leng Y, et al. Intake of fruit and vegetables and risk of esophageal squamous cell carcinoma: a meta-analysis of observational studies. Int J Cancer. 2013 Jul 15;133(2):473-85.Texto completo Resumo
76. Castro C, Peleteiro B, Lunet N. Modifiable factors and esophageal cancer: a systematic review of published meta-analyses. J Gastroenterol. 2018 Jan;53(1):37-51. Resumo
77. Bjelakovic G, Nikolova D, Simonetti RG, et al. Antioxidant supplements for preventing gastrointestinal cancers. Cochrane Database Syst Rev. 2008 Jul 16;(3):CD004183.Texto completo Resumo
78. Kang JH, Luben R, Alexandre L, et al. Dietary antioxidant intake and the risk of developing Barrett's oesophagus and oesophageal adenocarcinoma. Br J Cancer. 2018 Jun;118(12):1658-61.Texto completo Resumo
79. Myung SK, Yang HJ. Efficacy of vitamin and antioxidant supplements in prevention of esophageal cancer: meta-analysis of randomized controlled trials. J Cancer Prev. 2013 Jun;18(2):135-43.Texto completo Resumo
80. National Cancer Institute. Esophageal cancer prevention (PDQ®) - health professional version. Sep 2022 [internet publication].Texto completo
81. Corley DA, Kerlikowske K, Verma R, et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology. 2003 Jan;124(1):47-56.Texto completo Resumo
82. Wang F, Lv ZS, Fu YK. Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis. Dis Esophagus. 2011 Jul;24(5):318-24.Texto completo Resumo
83. Snider EJ, Kaz AM, Inadomi JM, et al. Chemoprevention of esophageal adenocarcinoma. Gastroenterol Rep (Oxf). 2020 Aug;8(4):253-60.Texto completo Resumo
84. Alexandre L, Clark AB, Cheong E, et al. Systematic review: potential preventive effects of statins against oesophageal adenocarcinoma. Aliment Pharmacol Ther. 2012 Aug;36(4):301-11.Texto completo Resumo
85. Thomas T, Loke Y, Beales ILP. Systematic review and meta-analysis: use of statins is associated with a reduced incidence of oesophageal adenocarcinoma. J Gastrointest Cancer. 2018 Dec;49(4):442-54.Texto completo Resumo
86. Arai J, Niikura R, Hayakawa Y, et al. Chemoprevention of oesophageal squamous-cell carcinoma and adenocarcinoma: a multicentre retrospective cohort study. Digestion. 2022;103(3):192-204.Texto completo Resumo
87. Ebright M, Krasna M. Overview: esophageal and proximal stomach malignancy. In: Sugarbaker DJ, ed. Adult chest surgery: concepts and procedures. New York, NY: McGraw-Hill; 2009:chapter 10.
88. Obermannová R, Alsina M, Cervantes A, et al; ESMO Guidelines Committee. Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Oct;33(10):992-1004.Texto completo Resumo
89. American College of Radiology. ACR appropriateness criteria: staging and follow-up of esophageal cancer. 2022 [internet publication].Texto completo
90. Picus D, Balfe DM, Koehler RE, et al. Computed tomography in the staging of esophageal carcinoma. Radiology. 1983 Feb;146(2):433-8. Resumo
91. Jayaprakasam VS, Yeh R, Ku GY, et al. Role of imaging in esophageal cancer management in 2020: update for radiologists. AJR Am J Roentgenol. 2020 Nov;215(5):1072-84.Texto completo Resumo
92. Dave UR, Williams AD, Wilson JA, et al. Esophageal cancer staging with endoscopic MR imaging: pilot study. Radiology. 2004 Jan;230(1):281-6. Resumo
93. Wong R, Walker-Dilks C, Raifu A. Evidence-based guideline recommendations on the use of positron emission tomography imaging in oesophageal cancer. Clin Oncol (R Coll Radiol). 2012 Mar;24(2):86-104. Resumo
94. Kwee RM. Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review. Radiology. 2010 Mar;254(3):707-17. Resumo
95. Rebollo Aguirre AC, Ramos-Font C, Villegas PR, et al. 18F-fluorodeoxiglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer: systematic review of the literature. Ann Surg. 2009 Aug;250(2):247-54. Resumo
96. Javeri H, Xiao L, Rohren E, et al. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer. 2009 Nov 15;115(22):5184-92.Texto completo Resumo
97. Chen YM, Pan XF, Tong LJ, et al. Can 18F-fluorodeoxyglucose positron emission tomography predict responses to neoadjuvant therapy in oesophageal cancer patients? A meta-analysis. Nucl Med Commun. 2011 Nov;32(11):1005-10. Resumo
98. Zhu W, Xing L, Yue J, et al. Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation: a systematic review and meta-analysis. Br J Radiol. 2012 Sep;85(1017):e694-701.Texto completo Resumo
99. Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000 Sep 15;18(18):3202-10. Resumo
100. Krill T, Baliss M, Roark R, et al. Accuracy of endoscopic ultrasound in esophageal cancer staging. J Thorac Dis. 2019 Aug;11(suppl 12):S1602-9.Texto completo Resumo
101. Vazquez-Sequeiros E, Wiersema MJ, Clain JE, et al. Impact of lymph node staging on therapy of esophageal carcinoma. Gastroenterology. 2003 Dec;125(6):1626-35.Texto completo Resumo
102. Puli SR, Reddy JB, Bechtold ML, et al. Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. World J Gastroenterol. 2008 Mar 14;14(10):1479-90.Texto completo Resumo
103. van Rossum PSN, Goense L, Meziani J, et al. Endoscopic biopsy and EUS for the detection of pathologic complete response after neoadjuvant chemoradiotherapy in esophageal cancer: a systematic review and meta-analysis. Gastrointest Endosc. 2016 May;83(5):866-79. Resumo
104. de Gouw DJJM, Klarenbeek BR, Driessen M, et al. Detecting pathological complete response in esophageal cancer after neoadjuvant therapy based on imaging techniques: a diagnostic systematic review and meta-analysis. J Thorac Oncol. 2019 Jul;14(7):1156-71.Texto completo Resumo
105. van der Bogt RD, van der Wilk BJ, Poley JW, et al. Endoscopic ultrasound and fine-needle aspiration for the detection of residual nodal disease after neoadjuvant chemoradiotherapy for esophageal cancer. Endoscopy. 2020 Mar;52(3):186-92. Resumo
106. Puli SR, Reddy JB, Bechtold ML, et al. Accuracy of endoscopic ultrasound in the diagnosis of distal and celiac axis lymph node metastasis in esophageal cancer: a meta-analysis and systematic review. Dig Dis Sci. 2008 Sep;53(9):2405-14. Resumo
107. Forbes N, Coelho-Prabhu N, Al-Haddad, et al; ASGE Standards of Practice Committee. Adverse events associated with EUS and EUS-guided procedures. Gastrointest Endosc. 2022 Jan;95(1):16-26. Resumo
108. de Graaf GW, Ayantunde AA, Parsons SL, et al. The role of staging laparoscopy in oesophagogastric cancers. Eur J Surg Oncol. 2007 Oct;33(8):988-92. Resumo
109. Mehta K, Bianco V, Awais O, et al. Minimally invasive staging of esophageal cancer. Ann Cardiothorac Surg. 2017 Mar;6(2):110-8.Texto completo Resumo
110. Luketich JD, Friedman DM, Weigel TL, et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg. 1999 Oct;68(4):1133-7.Texto completo Resumo
111. College of American Pathologists. Template for reporting results of DNA mismatch repair testing. Jun 2021 [internet publication].Texto completo
112. Kulangara K, Zhang N, Corigliano E, et al. Clinical utility of the Combined Positive Score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med. 2019 Mar;143(3):330-7.Texto completo Resumo
113. Doki Y, Ajani JA, Kato K, et al; CheckMate 648 Trial Investigators. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022 Feb 3;386(5):449-62.Texto completo Resumo
114. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687-97. Resumo
115. Cederholm T, Barazzoni R, Austin P, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr. 2017 Feb;36(1):49-64.Texto completo Resumo
116. Dunbar KB, Okolo P 3rd, Montgomery E, et al. Confocal laser endomicroscopy in Barrett's esophagus and endoscopically inapparent Barrett's neoplasia: a prospective, randomized, double-blind, controlled, crossover trial. Gastrointest Endosc. 2009 Oct;70(4):645-54.Texto completo Resumo
117. Curvers WL, Herrero LA, Wallace MB, et al. Endoscopic tri-modal imaging is more effective than standard endoscopy in identifying early-stage neoplasia in Barrett's esophagus. Gastroenterology. 2010 Oct;139(4):1106-14.Texto completo Resumo
118. Leggett CL, Gorospe EC. Application of confocal laser endomicroscopy in the diagnosis and management of Barrett's esophagus. Ann Gastroenterol. 2014;27(3):193-9.Texto completo Resumo
119. Amin MB, Edge S, Greene F, et al. (eds); American Joint Committee on Cancer. AJCC cancer staging manual. 8th ed. New York, NY: Springer; 2017.
120. Fotis D, Doukas M, Wijnhoven BP, et al. Submucosal invasion and risk of lymph node invasion in early Barrett's cancer: potential impact of different classification systems on patient management. United European Gastroenterol J. 2015 Dec;3(6):505-13.Texto completo Resumo
121. Participants in the Paris Workshop. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc. 2003 Dec;58(6 suppl):S3-43.Texto completo Resumo
122. Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T, et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2015 Sep;47(9):829-54.Texto completo Resumo
123. Gockel I, Sgourakis G, Lyros O, et al. Risk of lymph node metastasis in submucosal esophageal cancer: a review of surgically resected patients. Expert Rev Gastroenterol Hepatol. 2011 Jun;5(3):371-84. Resumo
124. Akutsu Y, Uesato M, Shuto K, et al. The overall prevalence of metastasis in T1 esophageal squamous cell carcinoma: a retrospective analysis of 295 patients. Ann Surg. 2013 Jun;257(6):1032-8. Resumo
125. Chen R, Ma S, Guan C, et al. The National Cohort of Esophageal Cancer - Prospective Cohort Study of Esophageal Cancer and Precancerous Lesions based on High-Risk Population in China (NCEC-HRP): study protocol. BMJ Open. 2019 Apr 3;9(4):e027360.Texto completo Resumo
126. Qumseya B, Sultan S, Bain P, et al; ASGE Standards of Practice Committee. ASGE guideline on screening and surveillance of Barrett's esophagus. Gastrointest Endosc. 2019 Sep;90(3):335-59.e2.Texto completo Resumo
127. Shaheen NJ, Falk GW, Iyer PG, et al; American College of Gastroenterology. ACG clinical guideline: diagnosis and management of Barrett's esophagus. Am J Gastroenterol. 2016 Jan;111(1):30-50.Texto completo Resumo
128. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014 Jan;63(1):7-42.Texto completo Resumo
129. Shaheen NJ, Falk GW, Iyer PG, et al. Diagnosis and management of Barrett's esophagus: an updated ACG guideline. Am J Gastroenterol. 2022 Apr 1;117(4):559-87.Texto completo Resumo
130. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009 May 28;360(22):2277-88.Texto completo Resumo
131. Shah MA, Kennedy EB, Catenacci DV, et al. Treatment of locally advanced esophageal carcinoma: ASCO guideline. J Clin Oncol. 2020 Aug 10;38(23):2677-94.Texto completo Resumo
132. Pech O, Bollschweiler E, Manner H, et al. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. Ann Surg. 2011 Jul;254(1):67-72. Resumo
133. National Institute for Health and Care Excellence. Oesophago-gastric cancer: assessment and management in adults. Jul 2023 [internet publication].Texto completo
134. Ahmed O, Ajani JA, Lee JH. Endoscopic management of esophageal cancer. World J Gastrointest Oncol. 2019 Oct 15;11(10):830-41.Texto completo Resumo
135. Ishihara R, Iishi H, Takeuchi Y, et al. Local recurrence of large squamous-cell carcinoma of the esophagus after endoscopic resection. Gastrointest Endosc. 2008 May;67(6):799-804. Resumo
136. Guo HM, Zhang XQ, Chen M, et al. Endoscopic submucosal dissection vs endoscopic mucosal resection for superficial esophageal cancer. World J Gastroenterol. 2014 May 14;20(18):5540-7.Texto completo Resumo
137. Cao Y, Liao C, Tan A, et al. Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract. Endoscopy. 2009 Sep;41(9):751-7. Resumo
138. ASGE standards of practice committee, Forbes N, Elhanafi SE, et al. American Society for Gastrointestinal Endoscopy guideline on endoscopic submucosal dissection for the management of early esophageal and gastric cancers: summary and recommendations. Gastrointest Endosc. 2023 Sep;98(3):271-84.Texto completo Resumo
139. di Pietro M, Canto MI, Fitzgerald RC. Endoscopic management of early adenocarcinoma and squamous cell carcinoma of the esophagus: screening, diagnosis, and therapy. Gastroenterology. 2018 Jan;154(2):421-36.Texto completo Resumo
140. Jezerskyte E, Saadeh LM, Hagens ERC, et al. Long-term health-related quality of life after McKeown and Ivor Lewis esophagectomy for esophageal carcinoma. Dis Esophagus. 2020 Nov 18;33(11):doaa022.Texto completo Resumo
141. Brusselaers N, Mattsson F, Lagergren J. Hospital and surgeon volume in relation to long-term survival after oesophagectomy: systematic review and meta-analysis. Gut. 2014 Sep;63(9):1393-400. Resumo
142. Derogar M, Sadr-Azodi O, Johar A, et al. Hospital and surgeon volume in relation to survival after esophageal cancer surgery in a population-based study. J Clin Oncol. 2013 Feb 10;31(5):551-7.Texto completo Resumo
143. Butler N, Collins S, Memon B, et al. Minimally invasive oesophagectomy: current status and future direction. Surg Endosc. 2011 Jul;25(7):2071-83. Resumo
144. National Institute for Health and Care Excellence. Minimally invasive oesophagectomy. Sep 2011 [internet publication].Texto completo
145. Peng JS, Kukar M, Mann GN, et al. Minimally invasive esophageal cancer surgery. Surg Oncol Clin N Am. 2019 Apr;28(2):177-200. Resumo
146. Yibulayin W, Abulizi S, Lv H, et al. Minimally invasive oesophagectomy versus open esophagectomy for resectable esophageal cancer: a meta-analysis. World J Surg Oncol. 2016 Dec 8;14(1):304.Texto completo Resumo
147. Biere SS, van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012 May 19;379(9829):1887-92. Resumo
148. Mariette C, Markar SR, Dabakuyo-Yonli TS, et al. Hybrid minimally invasive esophagectomy for esophageal cancer. N Engl J Med. 2019 Jan 10;380(2):152-62.Texto completo Resumo
149. van Hagen P, Hulshof MC, van Lanschot JJ, et al; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012 May 31;366(22):2074-84.Texto completo Resumo
150. Kidane B, Coughlin S, Vogt K, et al. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev. 2015 May 19;(5):CD001556.Texto completo Resumo
151. Conroy T, Galais MP, Raoul JL, et al; Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014 Mar;15(3):305-14. Resumo
152. Li QQ, Liu MZ, Hu YH, et al. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. Dis Esophagus. 2010 Apr;23(3):253-9.Texto completo Resumo
153. Rivera F, Romero C, Jimenez-Fonseca P, et al. Phase II study to evaluate the efficacy of trastuzumab in combination with capecitabine and oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. Cancer Chemother Pharmacol. 2019 Jun;83(6):1175-81.Texto completo Resumo
154. Shah MA, Kennedy EB, Alarcon-Rozas AE, et al. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline. J Clin Oncol. 2023 Mar 1;41(7):1470-91.Texto completo Resumo
155. Rha SY, Oh DY, Yañez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Nov;24(11):1181-95. Resumo
156. National Institute for Health and Care Excellence. Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer. Jun 2021 [internet publication].Texto completo
157. National Institute for Health and Care Excellence. Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. Feb 2023 [internet publication].Texto completo
158. Andre T, Berton D, Curigliano G, et al. Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: results from GARNET study. Paper presented at: American Society of Clinical Oncology 2021 gastrointestinal cancers symposium. Jan 15-17, 2021 (virtual). Colorectal cancer: abstract 9. J Clin Oncol. 2021 Jan 20;39(3_suppl):9.Texto completo
159. Barr H, Dix AJ, Kendall C, et al. Review article: the potential role for photodynamic therapy in the management of upper gastrointestinal disease. Aliment Pharmacol Ther. 2001 Mar;15(3):311-21.Texto completo Resumo
160. Weigel TL, Frumiento C, Gaumintz E. Endoluminal palliation for dysphagia secondary to esophageal carcinoma. Surg Clin North Am. 2002 Aug;82(4):747-61. Resumo
161. Chen M, Pennathur A, Luketich JD. Role of photodynamic therapy in unresectable esophageal and lung cancer. Lasers Surg Med. 2006 Jun;38(5):396-402. Resumo
162. Petersen BT, Chuttani R, Croffie J, et al. Photodynamic therapy for gastrointestinal disease. Gastrointest Endosc. 2006 Jun;63(7):927-32. Resumo
163. Greenwald BD, Dumot JA, Horwhat JD, et al. Safety, tolerability, and efficacy of endoscopic low-pressure liquid nitrogen spray cryotherapy in the esophagus. Dis Esophagus. 2010 Jan;23(1):13-9.Texto completo Resumo
164. National Institute for Health and Care Excellence. Balloon cryoablation for squamous dysplasia of the oesophagus. Oct 2020 [internet publication].Texto completo
165. Dai Y, Li C, Xie Y, et al. Interventions for dysphagia in oesophageal cancer. Cochrane Database Syst Rev. 2014 Oct 30;(10):CD005048.Texto completo Resumo
166. Merkow RP, Bilimoria KY, Keswani RN, et al. Treatment trends, risk of lymph node metastasis, and outcomes for localized esophageal cancer. J Natl Cancer Inst. 2014 Jul;106(7):dju133.Texto completo Resumo
167. Berry MF, Zeyer-Brunner J, Castleberry AW, et al. Treatment modalities for T1N0 esophageal cancers: a comparative analysis of local therapy versus surgical resection. J Thorac Oncol. 2013 Jun;8(6):796-802.Texto completo Resumo
168. Nentwich MF, von Loga K, Reeh M, et al. Depth of submucosal tumor infiltration and its relevance in lymphatic metastasis formation for T1b squamous cell and adenocarcinomas of the esophagus. J Gastrointest Surg. 2014 Feb;18(2):242-9. Resumo
169. Cen P, Hofstetter WL, Correa AM, et al. Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma. Cancer. 2008 Mar 1;112(5):1020-7.Texto completo Resumo
170. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002 Mar 1;20(5):1167-74. Resumo
171. Khushalani NI, Leichman CG, Proulx G, et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol. 2002 Jun 15;20(12):2844-50. Resumo
172. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992 Jun 11;326(24):1593-8.Texto completo Resumo
173. Cooper JS, Guo MD, Herskovic A, et al; Radiation Therapy Oncology Group. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA. 1999 May 5;281(17):1623-7.Texto completo Resumo
174. Oppedijk V, van der Gaast A, van Lanschot JJ, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 2014 Feb 10;32(5):385-91.Texto completo Resumo
175. Hirst NG, Gordon LG, Whiteman DC, et al. Is endoscopic surveillance for non-dysplastic Barrett's esophagus cost-effective? Review of economic evaluations. J Gastroenterol Hepatol. 2011 Feb;26(2):247-54. Resumo
176. Mariette C, Dahan L, Mornex F, et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol. 2014 Aug 10;32(23):2416-22.Texto completo Resumo
177. Kranzfelder M, Schuster T, Geinitz H, et al. Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg. 2011 Jun;98(6):768-83.Texto completo Resumo
178. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011 Jul;12(7):681-92. Resumo
179. Shapiro J, van Lanschot JJ, Hulshof MC, et al; CROSS study group. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015 Sep;16(9):1090-8. Resumo
180. Eyck BM, van Lanschot JJB, Hulshof MCCM, et al; CROSS Study Group. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol. 2021 Jun 20;39(18):1995-2004.Texto completo Resumo
181. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011 May 1;29(13):1715-21.Texto completo Resumo
182. Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019 May 11;393(10184):1948-57. Resumo
183. Cunningham D, Allum WH, Stenning SP, et al; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.Texto completo Resumo
184. Reynolds JV, Preston SR, O'Neill B, et al. Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452.) Paper presented at: 2021 ASCO annual general meeting. Jun 4-8, 2021 (virtual). Oral abstract session: gastrointestinal cancer - gastroesophageal, pancreatic, and hepatobiliary. J Clin Oncol 2021 May 20;39(15_suppl):4004.Texto completo
185. Hoeppner J, Lordick F, Brunner T, et al. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer. 2016 Jul 19;16:503.Texto completo Resumo
186. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005 Apr 1;23(10):2310-7.Texto completo Resumo
187. Bedenne L, Michel P, Bouché O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007 Apr 1;25(10):1160-8.Texto completo Resumo
188. Vellayappan BA, Soon YY, Ku GY, et al. Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer. Cochrane Database Syst Rev. 2017 Aug 22;(8):CD010511.Texto completo Resumo
189. Vincent J, Mariette C, Pezet D, et al; Fédération Francophone de Cancérologie Digestive (FFCD). Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD 9102 phase III trial: chemoradiation followed by surgery versus chemoradiation alone. Eur J Cancer. 2015 Sep;51(13):1683-93. Resumo
190. Markar S, Gronnier C, Duhamel A, et al. Salvage surgery after chemoradiotherapy in the management of esophageal cancer: is it a viable therapeutic option? J Clin Oncol. 2015 Nov 20;33(33):3866-73.Texto completo Resumo
191. Mitchell KG, Nelson DB, Corsini EM, et al. Morbidity following salvage esophagectomy for squamous cell carcinoma: the MD Anderson experience. Dis Esophagus. 2020 Mar 16;33(3):doz067.Texto completo Resumo
192. Cancer Research UK. Oesophageal cancer treatment statistics. 2021 [internet publication].Texto completo
193. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2003 Jun;185(6):538-43. Resumo
194. Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut. 2004 Jul;53(7):925-30.Texto completo Resumo
195. Brücher BL, Becker K, Lordick F, et al. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer. 2006 May 15;106(10):2119-27.Texto completo Resumo
196. Kelly RJ, Ajani JA, Kuzdzal J, et al; CheckMate 577 Investigators. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021 Apr 1;384(13):1191-203.Texto completo Resumo
197. National Institute for Health and Care Excellence. Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer. Nov 2021 [internet publication].Texto completo
198. Ferrell BR, Temel JS, Temin S, et al. Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017 Jan;35(1):96-112.Texto completo Resumo
199. Janmaat VT, Steyerberg EW, van der Gaast A, et al. Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. Cochrane Database Syst Rev. 2017 Nov 28;(11):CD004063.Texto completo Resumo
200. Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017 Aug 29;(8):CD004064.Texto completo Resumo
201. Montagnani F, Turrisi G, Marinozzi C, et al. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2011 Mar;14(1):50-5.Texto completo Resumo
202. Cunningham D, Starling N, Rao S, et al; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36-46.Texto completo Resumo
203. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006 Nov 1;24(31):4991-7.Texto completo Resumo
204. Findlay M, Cunningham D, Norman A, et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol. 1994 Sep;5(7):609-16.Texto completo Resumo
205. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997 Jan;15(1):261-7. Resumo
206. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002 Apr 15;20(8):1996-2004. Resumo
207. Elimova E, Janjigian YY, Mulcahy M, et al. It is time to stop using epirubicin to treat any patient with gastroesophageal adenocarcinoma. J Clin Oncol. 2017 Feb;35(4):475-7.Texto completo Resumo
208. Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008 Mar 20;26(9):1435-42.Texto completo Resumo
209. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008 Aug;19(8):1450-7.Texto completo Resumo
210. Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J Clin Oncol. 2014 Nov 1;32(31):3520-6.Texto completo Resumo
211. Shen L, Kato K, Kim SB, et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study. J Clin Oncol. 2022 Sep 10;40(26):3065-76.Texto completo Resumo
212. ClinicalTrials.gov. A study of tislelizumab (BGB-A317) versus chemotherapy as second line treatment in participants with advanced esophageal squamous cell carcinoma. NCT03430843. Dec 2023 [internet publication].Texto completo
213. Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023 May;24(5):483-95. Resumo
214. ClinicalTrials.gov. A study of tislelizumab (BGB-A317) in combination with chemotherapy as first line treatment in participants with advanced esophageal squamous cell carcinoma. NCT03783442. Nov 2023 [internet publication].Texto completo
215. Wainberg ZA, Enzinger PC, Kang YK, et al. Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT). Paper presented at: American Society of Clinical Oncology 2021 gastrointestinal cancers symposium. Esophageal and gastric cancer: abstract 160. J Clin Oncol. 2021 Jan 20;39(3_suppl):160.Texto completo
216. Catenacci DV, Tesfaye A, Tejani M, et al. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Future Oncol. 2019 Jun;15(18):2073-82.Texto completo Resumo
217. Wang ZX, Cui C, Yao J, et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial. Cancer Cell. 2022 Mar 14;40(3):277-88. Resumo
218. Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021 Sep 14;326(10):916-25.Texto completo Resumo
219. Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021 Aug;22(8):1081-92. Resumo
220. Ji Y, Du X, Zhu W, et al. Efficacy of concurrent chemoradiotherapy with S-1 vs radiotherapy alone for older patients with esophageal cancer: a multicenter randomized phase 3 clinical trial. JAMA Oncol. 2021 Oct 1;7(10):1459-66.Texto completo Resumo
221. van der Sluis PC, van der Horst S, May AM, et al. Robot-assisted minimally invasive thoracolaparoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer: a randomized controlled trial. Ann Surg. 2019 Apr;269(4):621-30. Resumo
222. de Groot EM, van der Horst S, Kingma BF, et al. Robot-assisted minimally invasive thoracolaparoscopic esophagectomy versus open esophagectomy: long-term follow-up of a randomized clinical trial. Dis Esophagus. 2020 Nov 26;33(supplement_2):doaa079.Texto completo Resumo
223. Mai Q, Mo Z, He J, et al. Feasibility and clinical value of computed tomography-guided 125I brachytherapy for pain palliation in patients with retroperitoneal lymph node metastases. J Cancer Res Ther. 2020;16(2):372-8.Texto completo Resumo
224. Zhang Y, Liu Z, Liang Y, et al. The effectiveness and prognostic factors of radioactive iodine-125 seed implantation for the treatment of cervical lymph node recurrence of esophageal squamous cell carcinoma after external beam radiation therapy. J Contemp Brachytherapy. 2020 Dec;12(6):579-85.Texto completo Resumo
225. Fu WH, Wang LH, Zhou ZM, et al. Comparison of conformal and intensity-modulated techniques for simultaneous integrated boost radiotherapy of upper esophageal carcinoma. World J Gastroenterol. 2004 Apr 15;10(8):1098-102.Texto completo Resumo
226. Chandra A, Guerrero TM, Liu HH, et al. Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol. 2005 Dec;77(3):247-53. Resumo
227. Tao H, Zhou Y, Yao C, et al. Phase II trial of intensity-modulated radiotherapy concurrent with chemotherapy for postoperative node-positive esophageal squamous cell carcinoma. Oncol Res. 2017 Sep 21;25(8):1357-62.Texto completo Resumo
228. Hulshof MCCM, Geijsen ED, Rozema T, et al. Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO Study). J Clin Oncol. 2021 Sep 1;39(25):2816-24.Texto completo Resumo
229. Crehange G, M'vondo C, Bertaut A, et al. Exclusive chemoradiotherapy with or without radiation dose escalation in esophageal cancer: multicenter phase 2/3 randomized trial CONCORDE (PRODIGE-26). CENTRAL (Cochrane Central Register of Controlled Trials). 2021 Oct 30;(10):CN-02321697.Texto completo
230. Chuong MD, Hallemeier CL, Jabbour SK, et al. Improving outcomes for esophageal cancer using proton beam therapy. Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):488-97. Resumo
231. Wang J, Wei C, Tucker SL, et al. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):885-91.Texto completo Resumo
232. Lin SH, Hobbs BP, Verma V, et al. Randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer. J Clin Oncol. 2020 May 10;38(14):1569-79.Texto completo Resumo
233. ClinicalTrials.gov. Comparing proton therapy to photon radiation therapy for esophageal cancer. NCT03801876. Mar 2023 [internet publication].Texto completo
234. Yu J, Zhang X, Liao L, et al. Motion-robust intensity-modulated proton therapy for distal esophageal cancer. Med Phys. 2016 Mar;43(3):1111-8. Resumo
235. Robb WB, Messager M, Dahan L, et al; Fédération Francophone de Cancérologie Digestive; Société Française de Radiothérapie Oncologique; Union des Centres de Lutte Contre le Cancer; Groupe Coopérateur Multidisciplinaire en Oncologie; French EsoGAstric Tumour working group - Fédération de Recherche En Chirurgie. Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone. Br J Surg. 2016 Jan;103(1):117-25.Texto completo Resumo
236. National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) Program. Esophagus: SEER 5-year relative survival rates, 2012-2018. 2021 [internet publication].Texto completo
237. Athauda A, Nankivell M, Langley RE, et al. Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: a pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03). Eur J Cancer. 2020 Sep;137:45-56.Texto completo Resumo
238. Gottlieb-Vedi E, Kauppila JH, Malietzis G, et al. Long-term survival in esophageal cancer after minimally invasive compared to open esophagectomy: a systematic review and meta-analysis. Ann Surg. 2019 Dec;270(6):1005-17. Resumo
239. Society for Surgery of the Alimentary Tract. SSAT patient care guidelines: surgical treatment of esophageal cancer. J Gastrointest Surg. 2007 Sep;11(9):1216-8. Resumo
240. van Kooten RT, Voeten DM, Steyerberg EW, et al. Patient-related prognostic factors for anastomotic leakage, major complications, and short-term mortality following esophagectomy for cancer: a systematic review and meta-analyses. Ann Surg Oncol. 2022 Feb;29(2):1358-73.Texto completo Resumo
241. Yasunaga H, Matsuyama Y, Ohe K, et al. Effects of hospital and surgeon case-volumes on postoperative complications and length of stay after esophagectomy in Japan. Surg Today. 2009;39(7):566-71. Resumo
242. Cooke DT, Lin GC, Lau CL, et al. Analysis of cervical esophagogastric anastomotic leaks after transhiatal esophagectomy: risk factors, presentation, and detection. Ann Thorac Surg. 2009 Jul;88(1):177-85.Texto completo Resumo
243. Zhou X, Yao Z, Bai H, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021 Sep;22(9):1265-74. Resumo
244. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: management of immunotherapy-related toxicities [internet publication].Texto completo
245. Powell N, Ibraheim H, Raine T, et al. British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. Lancet Gastroenterol Hepatol. 2020 Jul;5(7):679-97. Resumo
246. D'Journo XB, Martin J, Ferraro P, et al. The esophageal remnant after gastric interposition. Dis Esophagus. 2008;21(5):377-88.Texto completo Resumo
247. American Cancer Society. Living as an esophagus cancer survivor. Jun 2020 [internet publication].Texto completo
O uso deste conteúdo está sujeito ao nosso aviso legal